社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Waeisiong
New
IP属地：未知
+关注
帖子 · 61
帖子 · 61
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Waeisiong
Waeisiong
·
2021-08-05
nice
@pet：
$FRASER AND NEAVE, LIMITED(F99.SI)$steady and slow
$FRASER AND NEAVE, LIMITED(F99.SI)$steady and slow
看
3,048
回复
2
点赞
5
编组 21备份 2
分享
举报
Waeisiong
Waeisiong
·
2021-06-27
1 comment
非常抱歉，此主贴已删除
看
3,800
回复
4
点赞
10
编组 21备份 2
分享
举报
Waeisiong
Waeisiong
·
2021-06-21
Yoyo
非常抱歉，此主贴已删除
看
3,025
回复
评论
点赞
6
编组 21备份 2
分享
举报
Waeisiong
Waeisiong
·
2021-06-18
Feature?
Goldman sees Fed-driven dip in commodities as a 'buying opportunity'<blockquote>高盛将美联储推动的大宗商品下跌视为“买入机会”</blockquote>
(Reuters) - Goldman Sachs said on Friday the recent slip in commodities prices driven by the U.S. Fe
Goldman sees Fed-driven dip in commodities as a 'buying opportunity'<blockquote>高盛将美联储推动的大宗商品下跌视为“买入机会”</blockquote>
看
3,956
回复
评论
点赞
3
编组 21备份 2
分享
举报
Waeisiong
Waeisiong
·
2021-06-17
Too bad...
Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote>
Company plunges After Covid Shot Falls Short With 47% Efficacy Effectiveness is far below that seen
Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote>
看
2,412
回复
5
点赞
2
编组 21备份 2
分享
举报
Waeisiong
Waeisiong
·
2021-06-16
Comment pls
非常抱歉，此主贴已删除
看
3,951
回复
5
点赞
8
编组 21备份 2
分享
举报
Waeisiong
Waeisiong
·
2021-06-15
Nice !
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote>
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote>
看
2,498
回复
评论
点赞
3
编组 21备份 2
分享
举报
Waeisiong
Waeisiong
·
2021-06-15
Nice !
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote>
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote>
看
2,489
回复
评论
点赞
1
编组 21备份 2
分享
举报
Waeisiong
Waeisiong
·
2021-06-14
Comment pls
非常抱歉，此主贴已删除
看
2,309
回复
4
点赞
3
编组 21备份 2
分享
举报
Waeisiong
Waeisiong
·
2021-06-12
Pls comment thanks
非常抱歉，此主贴已删除
看
2,516
回复
5
点赞
4
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3581590310925129","uuid":"3581590310925129","gmtCreate":1618496561194,"gmtModify":1619154614057,"name":"Waeisiong","pinyin":"waeisiong","introduction":"","introductionEn":null,"signature":"New","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":21,"headSize":473,"tweetSize":61,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.10","exceedPercentage":"60.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":890708003,"gmtCreate":1628131494602,"gmtModify":1631889812866,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/890708003","repostId":"805314024","repostType":1,"repost":{"id":805314024,"gmtCreate":1627860781468,"gmtModify":1631890839294,"author":{"id":"3574914454410809","authorId":"3574914454410809","name":"pet","avatar":"https://static.tigerbbs.com/d8bb8cf9a25355b93399ce59a269665b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574914454410809","idStr":"3574914454410809"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/F99.SI\">$FRASER AND NEAVE, LIMITED(F99.SI)$</a>steady and slow","listText":"<a href=\"https://laohu8.com/S/F99.SI\">$FRASER AND NEAVE, LIMITED(F99.SI)$</a>steady and slow","text":"$FRASER AND NEAVE, LIMITED(F99.SI)$steady and slow","images":[{"img":"https://static.tigerbbs.com/f0267bb4fd19c63e0e02aa4d96aef76f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805314024","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3048,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127046774,"gmtCreate":1624807618598,"gmtModify":1631889812870,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"1 comment","listText":"1 comment","text":"1 comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/127046774","repostId":"2146090006","repostType":4,"isVote":1,"tweetType":1,"viewCount":3800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167114611,"gmtCreate":1624251888333,"gmtModify":1631889812871,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"Yoyo","listText":"Yoyo","text":"Yoyo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167114611","repostId":"1154249454","repostType":4,"isVote":1,"tweetType":1,"viewCount":3025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166551845,"gmtCreate":1624019373087,"gmtModify":1631889812878,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"Feature?","listText":"Feature?","text":"Feature?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166551845","repostId":"1131081247","repostType":4,"repost":{"id":"1131081247","kind":"news","pubTimestamp":1624019171,"share":"https://www.laohunote.com/m/news/1131081247?lang=zh_CN&edition=full","pubTime":"2021-06-18 20:26","market":"fut","language":"en","title":"Goldman sees Fed-driven dip in commodities as a 'buying opportunity'<blockquote>高盛将美联储推动的大宗商品下跌视为“买入机会”</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1131081247","media":"Reuters","summary":"(Reuters) - Goldman Sachs said on Friday the recent slip in commodities prices driven by the U.S. Fe","content":"<p>(Reuters) - Goldman Sachs said on Friday the recent slip in commodities prices driven by the U.S. Federal Reserve’s decision to bring forward projections for interest rate hikes into 2023 was a buying opportunity for investors.</p><p><blockquote>(路透社）--高盛（Goldman Sachs）周五表示，由于美国联邦储备委员会决定将加息预测提前至2023年，近期大宗商品价格下滑，这对投资者来说是一个买入机会。</blockquote></p><p> “The bullish commodity thesis is neither about inflation risks nor Fed forward guidance. It is about scarcity and strong physical demand,” the Wall Street bank said in a note.</p><p><blockquote>“看涨大宗商品的论点既不是关于通胀风险，也不是关于美联储的前瞻性指引。而是关于稀缺性和强劲的实物需求，”这家华尔街银行在一份报告中说。</blockquote></p><p> Physical scarcity, caused by robust demand growth and inelastic supply, could drive Brent crude oil prices to average $80 in the third quarter, with potential spikes above that level, Goldman analysts wrote.</p><p><blockquote>高盛分析师写道，强劲的需求增长和缺乏弹性的供应造成的实物短缺可能会推动布伦特原油价格在第三季度平均升至 80 美元，并可能高于该水平。</blockquote></p><p> Prices of commodities including oil, gold and copper fell as the U.S. dollar surged on the Federal Reserve’s outlook on interest rate hikes.</p><p><blockquote>由于美联储的加息前景导致美元飙升，包括石油、黄金和铜在内的大宗商品价格下跌。</blockquote></p><p> But oil prices were still close to multi-year highs, while gold has since seen a slight rebound, and copper was en route to its biggest weekly decline since March 2020.</p><p><blockquote>但油价仍接近多年高点，而黄金此后略有反弹，铜价有望创下 2020 年 3 月以来的最大单周跌幅。</blockquote></p><p> The copper market also remains on course for deficit conditions both over the remainder of this year and into 2022, the bank said, adding recent dips should be viewed as a longer-term buying opportunity.</p><p><blockquote>该银行表示，今年剩余时间和 2022 年铜市场仍处于赤字状态，并补充说，最近的下跌应被视为长期买入机会。</blockquote></p><p> A recovery in commodities markets excluding energy markets, however, is likely to be slower than from recent sell-offs as transient shocks from weather and Chinese-mandated repositioning have generated negative technical breakthroughs, Goldman warned.</p><p><blockquote>然而，高盛警告称，不包括能源市场的大宗商品市场的复苏速度可能会慢于近期的抛售，因为天气和中国强制重新定位带来了负面的技术突破。</blockquote></p><p> Earlier this month, China’s state planner renewed a pledge to step up monitoring of commodity prices and strengthen supervision of spot and futures markets, as producer inflation in the country hit over 12 year-highs.</p><p><blockquote>本月早些时候，中国国家规划师再次承诺加强对大宗商品价格的监测，并加强对现货和期货市场的监管，因为中国的生产者通胀率创下了 12 年来的新高。</blockquote></p><p> Goldman also viewed gold as under-valued relative to both real and nominal fundamentals.</p><p><blockquote>高盛还认为，相对于真实和名义基本面，黄金被低估。</blockquote></p><p> “In fact, gold is now pricing a Goldilocks scenario of strong growth without any inflation, implying limited demand for it as either a defensive asset or inflation hedge.”</p><p><blockquote>“事实上，黄金现在的定价是在没有任何通胀的情况下实现强劲增长的金发姑娘情景，这意味着对黄金作为防御性资产或通胀对冲资产的需求有限。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman sees Fed-driven dip in commodities as a 'buying opportunity'<blockquote>高盛将美联储推动的大宗商品下跌视为“买入机会”</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman sees Fed-driven dip in commodities as a 'buying opportunity'<blockquote>高盛将美联储推动的大宗商品下跌视为“买入机会”</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-06-18 20:26</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - Goldman Sachs said on Friday the recent slip in commodities prices driven by the U.S. Federal Reserve’s decision to bring forward projections for interest rate hikes into 2023 was a buying opportunity for investors.</p><p><blockquote>(路透社）--高盛（Goldman Sachs）周五表示，由于美国联邦储备委员会决定将加息预测提前至2023年，近期大宗商品价格下滑，这对投资者来说是一个买入机会。</blockquote></p><p> “The bullish commodity thesis is neither about inflation risks nor Fed forward guidance. It is about scarcity and strong physical demand,” the Wall Street bank said in a note.</p><p><blockquote>“看涨大宗商品的论点既不是关于通胀风险，也不是关于美联储的前瞻性指引。而是关于稀缺性和强劲的实物需求，”这家华尔街银行在一份报告中说。</blockquote></p><p> Physical scarcity, caused by robust demand growth and inelastic supply, could drive Brent crude oil prices to average $80 in the third quarter, with potential spikes above that level, Goldman analysts wrote.</p><p><blockquote>高盛分析师写道，强劲的需求增长和缺乏弹性的供应造成的实物短缺可能会推动布伦特原油价格在第三季度平均升至 80 美元，并可能高于该水平。</blockquote></p><p> Prices of commodities including oil, gold and copper fell as the U.S. dollar surged on the Federal Reserve’s outlook on interest rate hikes.</p><p><blockquote>由于美联储的加息前景导致美元飙升，包括石油、黄金和铜在内的大宗商品价格下跌。</blockquote></p><p> But oil prices were still close to multi-year highs, while gold has since seen a slight rebound, and copper was en route to its biggest weekly decline since March 2020.</p><p><blockquote>但油价仍接近多年高点，而黄金此后略有反弹，铜价有望创下 2020 年 3 月以来的最大单周跌幅。</blockquote></p><p> The copper market also remains on course for deficit conditions both over the remainder of this year and into 2022, the bank said, adding recent dips should be viewed as a longer-term buying opportunity.</p><p><blockquote>该银行表示，今年剩余时间和 2022 年铜市场仍处于赤字状态，并补充说，最近的下跌应被视为长期买入机会。</blockquote></p><p> A recovery in commodities markets excluding energy markets, however, is likely to be slower than from recent sell-offs as transient shocks from weather and Chinese-mandated repositioning have generated negative technical breakthroughs, Goldman warned.</p><p><blockquote>然而，高盛警告称，不包括能源市场的大宗商品市场的复苏速度可能会慢于近期的抛售，因为天气和中国强制重新定位带来了负面的技术突破。</blockquote></p><p> Earlier this month, China’s state planner renewed a pledge to step up monitoring of commodity prices and strengthen supervision of spot and futures markets, as producer inflation in the country hit over 12 year-highs.</p><p><blockquote>本月早些时候，中国国家规划师再次承诺加强对大宗商品价格的监测，并加强对现货和期货市场的监管，因为中国的生产者通胀率创下了 12 年来的新高。</blockquote></p><p> Goldman also viewed gold as under-valued relative to both real and nominal fundamentals.</p><p><blockquote>高盛还认为，相对于真实和名义基本面，黄金被低估。</blockquote></p><p> “In fact, gold is now pricing a Goldilocks scenario of strong growth without any inflation, implying limited demand for it as either a defensive asset or inflation hedge.”</p><p><blockquote>“事实上，黄金现在的定价是在没有任何通胀的情况下实现强劲增长的金发姑娘情景，这意味着对黄金作为防御性资产或通胀对冲资产的需求有限。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/commodities-research-goldman/goldman-sees-fed-driven-dip-in-commodities-as-a-buying-opportunity-idUSL3N2O02QT\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛"},"source_url":"https://www.reuters.com/article/commodities-research-goldman/goldman-sees-fed-driven-dip-in-commodities-as-a-buying-opportunity-idUSL3N2O02QT","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131081247","content_text":"(Reuters) - Goldman Sachs said on Friday the recent slip in commodities prices driven by the U.S. Federal Reserve’s decision to bring forward projections for interest rate hikes into 2023 was a buying opportunity for investors.\n“The bullish commodity thesis is neither about inflation risks nor Fed forward guidance. It is about scarcity and strong physical demand,” the Wall Street bank said in a note.\nPhysical scarcity, caused by robust demand growth and inelastic supply, could drive Brent crude oil prices to average $80 in the third quarter, with potential spikes above that level, Goldman analysts wrote.\nPrices of commodities including oil, gold and copper fell as the U.S. dollar surged on the Federal Reserve’s outlook on interest rate hikes.\nBut oil prices were still close to multi-year highs, while gold has since seen a slight rebound, and copper was en route to its biggest weekly decline since March 2020.\nThe copper market also remains on course for deficit conditions both over the remainder of this year and into 2022, the bank said, adding recent dips should be viewed as a longer-term buying opportunity.\nA recovery in commodities markets excluding energy markets, however, is likely to be slower than from recent sell-offs as transient shocks from weather and Chinese-mandated repositioning have generated negative technical breakthroughs, Goldman warned.\nEarlier this month, China’s state planner renewed a pledge to step up monitoring of commodity prices and strengthen supervision of spot and futures markets, as producer inflation in the country hit over 12 year-highs.\nGoldman also viewed gold as under-valued relative to both real and nominal fundamentals.\n“In fact, gold is now pricing a Goldilocks scenario of strong growth without any inflation, implying limited demand for it as either a defensive asset or inflation hedge.”","news_type":1,"symbols_score_info":{"GS":0.9}},"isVote":1,"tweetType":1,"viewCount":3956,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163239232,"gmtCreate":1623885689126,"gmtModify":1631889812877,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"Too bad...","listText":"Too bad...","text":"Too bad...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/163239232","repostId":"1199737134","repostType":4,"repost":{"id":"1199737134","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623885157,"share":"https://www.laohunote.com/m/news/1199737134?lang=zh_CN&edition=full","pubTime":"2021-06-17 07:12","market":"us","language":"en","title":"Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199737134","media":"Tiger Newspress","summary":"Company plunges After Covid Shot Falls Short With 47% Efficacy\nEffectiveness is far below that seen ","content":"<p><ul> <li>Company plunges After Covid Shot Falls Short With 47% Efficacy</li> <li>Effectiveness is far below that seen with other mRNA vaccines</li> </ul> CureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its Covid-19 vaccine was 47% effective, well short of the high bar set by other messenger RNA shots.</p><p><blockquote><ul><li>新冠疫苗有效率低于 47%，公司股价暴跌</li><li>有效性远低于其他mRNA疫苗</li></ul>CureVac NV 股价暴跌，此前一项大型研究的初步分析发现，其 Covid-19 疫苗的有效率为 47%，远低于其他信使 RNA 疫苗设定的高标准。</blockquote></p><p> The interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement. CureVac declined to say how many who got the shot got sick or how many received a placebo. But the results suggest the vaccine works less well for older people than in a younger population, Chief Technology Officer Mariola Fotin-Mleczek said in an interview Wednesday.</p><p><blockquote>这家德国公司在一份声明中表示，对约 40,000 名志愿者数据的中期分析包括 134 例 Covid 病例。CureVac 拒绝透露有多少注射者生病，或者有多少人接受了安慰剂。但首席技术官 Mariola Fotin-Mleczek 在周三接受采访时表示，结果表明，该疫苗对老年人的效果不如对年轻人好。</blockquote></p><p> Though preliminary, the results throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said.</p><p><blockquote>尽管是初步的，但随着世界各地的富裕国家迅速采取行动，用已经可用的疫苗为其人口接种疫苗，这些结果使疫苗的未来受到质疑。尽管如此，CureVac 首席执行官 Franz-Werner Haas 表示，CureVac 仍将完成试验并计划获得批准。</blockquote></p><p> “There is a huge need for vaccine, and I think we can still make a contribution,” Haas said.</p><p><blockquote>“哈斯说：”对疫苗的需求非常大，我认为我们仍然可以做出贡献。</blockquote></p><p> The company’s shares fell more than 49% in post-market trading after being up 17% this year through Wednesday’s close.</p><p><blockquote>截至周三收盘，该公司股价今年上涨了 17%，但在盘后交易中下跌了 49% 以上。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6ec3f2e05cfbc6c7d87c3fa174f459c\" tg-width=\"1302\" tg-height=\"663\"></p><p><blockquote></blockquote></p><p> In April, Elon Musk tweeted about CureVac, which Tesla Inc. has partnered with on a vaccine printer,saying it “sounds like they’re a few months away from regulatory approval.” He added that “a tidal wave of vaccine is coming this summer.” He later deleted the tweet.</p><p><blockquote>今年 4 月，埃隆-马斯克（Elon Musk）在推特上谈到了 CureVac，称 “听起来他们离监管部门的批准还有几个月的时间”。他补充说，“今年夏天将出现一波疫苗接种浪潮”。他后来删除了这条推文。</blockquote></p><p> The shot could be a boost in the developing world, since it doesn’t require the deep freezing needed for other Covid shots. Partly owned by the German government, CureVac has forged partnerships with Bayer AG,GlaxoSmithKline Plc and the U.K. government aimed at speeding production of its shot and future versions that will target mutated strains.</p><p><blockquote>这种注射可能会对发展中国家起到推动作用，因为它不需要其他 Covid 注射所需的深度冷冻。CureVac 部分归德国政府所有，已与拜耳公司、葛兰素史克公司和英国建立了合作伙伴关系。政府的目标是加快其疫苗的生产，以及针对突变菌株的未来版本。</blockquote></p><p> The data comes as the world is at something of a crossroads in the Covid fight, with global infections falling even as outbreaks in places with less access to vaccines serve as a reminder that the pandemic is far from over. The wealthiest countries have taken an outsize share of the more than 2.4 billion shots administered so far.</p><p><blockquote>这些数据发布之际，世界正处于抗击新冠疫情的十字路口，全球感染人数正在下降，尽管疫苗较少的地方爆发疫情提醒人们，疫情远未结束。迄今为止，最富裕的国家已经在超过24亿次注射中占据了很大一部分。</blockquote></p><p> The proliferation of variants in the CureVac trial is testimony to how the pandemic has changed since the first large vaccine clinical trials were run last year.</p><p><blockquote>CureVac试验中变异体的扩散证明了自去年进行第一次大型疫苗临床试验以来，疫情发生了怎样的变化。</blockquote></p><p> <b>Genetic Sequencing</b></p><p><blockquote><b>基因测序</b></blockquote></p><p> CureVac’s researchers genetically sequenced 124 of the 134 cases they included in their analysis. Just one of the sequenced cases was due to the original SARS-CoV-2 virus first identified in Wuhan, China. The rest came from a range of variants, including 21% of cases attributable to a new variant called lambda that was first identified in Peru.</p><p><blockquote>CureVac 的研究人员对他们分析中包含的 134 个病例中的 124 个进行了基因测序。只有一例测序病例是由中国武汉首次发现的原始新型冠状病毒病毒引起的。其余的来自一系列变种，包括21%的病例可归因于在秘鲁首次发现的一种名为lambda的新变种。</blockquote></p><p> TheWorld Health Organization added lambda to its watchlist as a variant of interest on Monday.</p><p><blockquote>世界卫生组织周一将 lambda 列入其观察名单，作为感兴趣的变体。</blockquote></p><p> Some 57% of the Covid cases in the study were due to so-called variants of concern, the four variants that the World Health Organization has deemed the most worrying. Most of these -- about 41% of all the cases -- were due to the alpha variant first observed in the U.K., CureVac said.</p><p><blockquote>研究中约57%的Covid病例是由所谓的令人担忧的变异引起的，这是世界卫生组织认为最令人担忧的四种变异。CureVac 表示，其中大部分（约占所有病例的 41%）是由英国首次观察到的 alpha 变种引起的。</blockquote></p><p> That variant is now the most common in the U.S., and other vaccines, including shots from Pfizer Inc. and BioNTech SE as well as Novavax Inc., have shown themselves effective against it. CureVac didn’t release detailed data about how its shot performed against each of the variants.</p><p><blockquote>这种变异现在在美国最常见，其他疫苗，包括辉瑞公司和BioNTech SE以及Novavax公司的疫苗，都已被证明对它有效。CureVac 没有公布其针对每种变种的注射效果的详细数据。</blockquote></p><p> <b>Final Readout</b></p><p><blockquote><b>最终读数</b></blockquote></p><p> More details will emerge in the final readout of the study, which will include more than 200 Covid cases and could come within two or three weeks, CureVac said.</p><p><blockquote>CureVac 表示，更多细节将出现在该研究的最终读数中，该研究将包括 200 多个 Covid 病例，可能会在两到三周内公布。</blockquote></p><p> Like the shots from Moderna Inc. and the Pfizer-BioNtech alliance, CureVac’s vaccine relies on mRNA, enlisting the body’s own cells as vaccine factories. Unproven until last year, the technology has now catapulted to the forefront of the global fight against Covid.</p><p><blockquote>与 Moderna Inc. 和辉瑞-BioNtech 联盟的疫苗一样，CureVac 的疫苗依赖于 mRNA，利用人体自身的细胞作为疫苗工厂。直到去年才得到证实，这项技术现在已经跃居全球抗击新冠疫情的前沿。</blockquote></p><p> CureVac’s shot, though, is subtly different than its competitors, because it uses an unmodified form of mRNA.</p><p><blockquote>不过，CureVac 的疫苗与其竞争对手略有不同，因为它使用的是未经修饰的 mRNA。</blockquote></p><p> CureVac has said it plans to supply 300 million vaccine doses this year, enough to immunize 150 million people. Together with partners, it has said it will supply more than 1 billion doses in 2022.</p><p><blockquote>CureVac表示，计划今年供应3亿剂疫苗，足以为1.5亿人接种疫苗。该公司表示，将与合作伙伴一起在 2022 年供应超过 10 亿剂疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMusk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-17 07:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><ul> <li>Company plunges After Covid Shot Falls Short With 47% Efficacy</li> <li>Effectiveness is far below that seen with other mRNA vaccines</li> </ul> CureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its Covid-19 vaccine was 47% effective, well short of the high bar set by other messenger RNA shots.</p><p><blockquote><ul><li>新冠疫苗有效率低于 47%，公司股价暴跌</li><li>有效性远低于其他mRNA疫苗</li></ul>CureVac NV 股价暴跌，此前一项大型研究的初步分析发现，其 Covid-19 疫苗的有效率为 47%，远低于其他信使 RNA 疫苗设定的高标准。</blockquote></p><p> The interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement. CureVac declined to say how many who got the shot got sick or how many received a placebo. But the results suggest the vaccine works less well for older people than in a younger population, Chief Technology Officer Mariola Fotin-Mleczek said in an interview Wednesday.</p><p><blockquote>这家德国公司在一份声明中表示，对约 40,000 名志愿者数据的中期分析包括 134 例 Covid 病例。CureVac 拒绝透露有多少注射者生病，或者有多少人接受了安慰剂。但首席技术官 Mariola Fotin-Mleczek 在周三接受采访时表示，结果表明，该疫苗对老年人的效果不如对年轻人好。</blockquote></p><p> Though preliminary, the results throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said.</p><p><blockquote>尽管是初步的，但随着世界各地的富裕国家迅速采取行动，用已经可用的疫苗为其人口接种疫苗，这些结果使疫苗的未来受到质疑。尽管如此，CureVac 首席执行官 Franz-Werner Haas 表示，CureVac 仍将完成试验并计划获得批准。</blockquote></p><p> “There is a huge need for vaccine, and I think we can still make a contribution,” Haas said.</p><p><blockquote>“哈斯说：”对疫苗的需求非常大，我认为我们仍然可以做出贡献。</blockquote></p><p> The company’s shares fell more than 49% in post-market trading after being up 17% this year through Wednesday’s close.</p><p><blockquote>截至周三收盘，该公司股价今年上涨了 17%，但在盘后交易中下跌了 49% 以上。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6ec3f2e05cfbc6c7d87c3fa174f459c\" tg-width=\"1302\" tg-height=\"663\"></p><p><blockquote></blockquote></p><p> In April, Elon Musk tweeted about CureVac, which Tesla Inc. has partnered with on a vaccine printer,saying it “sounds like they’re a few months away from regulatory approval.” He added that “a tidal wave of vaccine is coming this summer.” He later deleted the tweet.</p><p><blockquote>今年 4 月，埃隆-马斯克（Elon Musk）在推特上谈到了 CureVac，称 “听起来他们离监管部门的批准还有几个月的时间”。他补充说，“今年夏天将出现一波疫苗接种浪潮”。他后来删除了这条推文。</blockquote></p><p> The shot could be a boost in the developing world, since it doesn’t require the deep freezing needed for other Covid shots. Partly owned by the German government, CureVac has forged partnerships with Bayer AG,GlaxoSmithKline Plc and the U.K. government aimed at speeding production of its shot and future versions that will target mutated strains.</p><p><blockquote>这种注射可能会对发展中国家起到推动作用，因为它不需要其他 Covid 注射所需的深度冷冻。CureVac 部分归德国政府所有，已与拜耳公司、葛兰素史克公司和英国建立了合作伙伴关系。政府的目标是加快其疫苗的生产，以及针对突变菌株的未来版本。</blockquote></p><p> The data comes as the world is at something of a crossroads in the Covid fight, with global infections falling even as outbreaks in places with less access to vaccines serve as a reminder that the pandemic is far from over. The wealthiest countries have taken an outsize share of the more than 2.4 billion shots administered so far.</p><p><blockquote>这些数据发布之际，世界正处于抗击新冠疫情的十字路口，全球感染人数正在下降，尽管疫苗较少的地方爆发疫情提醒人们，疫情远未结束。迄今为止，最富裕的国家已经在超过24亿次注射中占据了很大一部分。</blockquote></p><p> The proliferation of variants in the CureVac trial is testimony to how the pandemic has changed since the first large vaccine clinical trials were run last year.</p><p><blockquote>CureVac试验中变异体的扩散证明了自去年进行第一次大型疫苗临床试验以来，疫情发生了怎样的变化。</blockquote></p><p> <b>Genetic Sequencing</b></p><p><blockquote><b>基因测序</b></blockquote></p><p> CureVac’s researchers genetically sequenced 124 of the 134 cases they included in their analysis. Just one of the sequenced cases was due to the original SARS-CoV-2 virus first identified in Wuhan, China. The rest came from a range of variants, including 21% of cases attributable to a new variant called lambda that was first identified in Peru.</p><p><blockquote>CureVac 的研究人员对他们分析中包含的 134 个病例中的 124 个进行了基因测序。只有一例测序病例是由中国武汉首次发现的原始新型冠状病毒病毒引起的。其余的来自一系列变种，包括21%的病例可归因于在秘鲁首次发现的一种名为lambda的新变种。</blockquote></p><p> TheWorld Health Organization added lambda to its watchlist as a variant of interest on Monday.</p><p><blockquote>世界卫生组织周一将 lambda 列入其观察名单，作为感兴趣的变体。</blockquote></p><p> Some 57% of the Covid cases in the study were due to so-called variants of concern, the four variants that the World Health Organization has deemed the most worrying. Most of these -- about 41% of all the cases -- were due to the alpha variant first observed in the U.K., CureVac said.</p><p><blockquote>研究中约57%的Covid病例是由所谓的令人担忧的变异引起的，这是世界卫生组织认为最令人担忧的四种变异。CureVac 表示，其中大部分（约占所有病例的 41%）是由英国首次观察到的 alpha 变种引起的。</blockquote></p><p> That variant is now the most common in the U.S., and other vaccines, including shots from Pfizer Inc. and BioNTech SE as well as Novavax Inc., have shown themselves effective against it. CureVac didn’t release detailed data about how its shot performed against each of the variants.</p><p><blockquote>这种变异现在在美国最常见，其他疫苗，包括辉瑞公司和BioNTech SE以及Novavax公司的疫苗，都已被证明对它有效。CureVac 没有公布其针对每种变种的注射效果的详细数据。</blockquote></p><p> <b>Final Readout</b></p><p><blockquote><b>最终读数</b></blockquote></p><p> More details will emerge in the final readout of the study, which will include more than 200 Covid cases and could come within two or three weeks, CureVac said.</p><p><blockquote>CureVac 表示，更多细节将出现在该研究的最终读数中，该研究将包括 200 多个 Covid 病例，可能会在两到三周内公布。</blockquote></p><p> Like the shots from Moderna Inc. and the Pfizer-BioNtech alliance, CureVac’s vaccine relies on mRNA, enlisting the body’s own cells as vaccine factories. Unproven until last year, the technology has now catapulted to the forefront of the global fight against Covid.</p><p><blockquote>与 Moderna Inc. 和辉瑞-BioNtech 联盟的疫苗一样，CureVac 的疫苗依赖于 mRNA，利用人体自身的细胞作为疫苗工厂。直到去年才得到证实，这项技术现在已经跃居全球抗击新冠疫情的前沿。</blockquote></p><p> CureVac’s shot, though, is subtly different than its competitors, because it uses an unmodified form of mRNA.</p><p><blockquote>不过，CureVac 的疫苗与其竞争对手略有不同，因为它使用的是未经修饰的 mRNA。</blockquote></p><p> CureVac has said it plans to supply 300 million vaccine doses this year, enough to immunize 150 million people. Together with partners, it has said it will supply more than 1 billion doses in 2022.</p><p><blockquote>CureVac表示，计划今年供应3亿剂疫苗，足以为1.5亿人接种疫苗。该公司表示，将与合作伙伴一起在 2022 年供应超过 10 亿剂疫苗。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVAC":"CureVac B.V."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199737134","content_text":"Company plunges After Covid Shot Falls Short With 47% Efficacy\nEffectiveness is far below that seen with other mRNA vaccines\n\nCureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its Covid-19 vaccine was 47% effective, well short of the high bar set by other messenger RNA shots.\nThe interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement. CureVac declined to say how many who got the shot got sick or how many received a placebo. But the results suggest the vaccine works less well for older people than in a younger population, Chief Technology Officer Mariola Fotin-Mleczek said in an interview Wednesday.\nThough preliminary, the results throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said.\n“There is a huge need for vaccine, and I think we can still make a contribution,” Haas said.\nThe company’s shares fell more than 49% in post-market trading after being up 17% this year through Wednesday’s close.\n\nIn April, Elon Musk tweeted about CureVac, which Tesla Inc. has partnered with on a vaccine printer,saying it “sounds like they’re a few months away from regulatory approval.” He added that “a tidal wave of vaccine is coming this summer.” He later deleted the tweet.\nThe shot could be a boost in the developing world, since it doesn’t require the deep freezing needed for other Covid shots. Partly owned by the German government, CureVac has forged partnerships with Bayer AG,GlaxoSmithKline Plc and the U.K. government aimed at speeding production of its shot and future versions that will target mutated strains.\nThe data comes as the world is at something of a crossroads in the Covid fight, with global infections falling even as outbreaks in places with less access to vaccines serve as a reminder that the pandemic is far from over. The wealthiest countries have taken an outsize share of the more than 2.4 billion shots administered so far.\nThe proliferation of variants in the CureVac trial is testimony to how the pandemic has changed since the first large vaccine clinical trials were run last year.\nGenetic Sequencing\nCureVac’s researchers genetically sequenced 124 of the 134 cases they included in their analysis. Just one of the sequenced cases was due to the original SARS-CoV-2 virus first identified in Wuhan, China. The rest came from a range of variants, including 21% of cases attributable to a new variant called lambda that was first identified in Peru.\nTheWorld Health Organization added lambda to its watchlist as a variant of interest on Monday.\nSome 57% of the Covid cases in the study were due to so-called variants of concern, the four variants that the World Health Organization has deemed the most worrying. Most of these -- about 41% of all the cases -- were due to the alpha variant first observed in the U.K., CureVac said.\nThat variant is now the most common in the U.S., and other vaccines, including shots from Pfizer Inc. and BioNTech SE as well as Novavax Inc., have shown themselves effective against it. CureVac didn’t release detailed data about how its shot performed against each of the variants.\nFinal Readout\nMore details will emerge in the final readout of the study, which will include more than 200 Covid cases and could come within two or three weeks, CureVac said.\nLike the shots from Moderna Inc. and the Pfizer-BioNtech alliance, CureVac’s vaccine relies on mRNA, enlisting the body’s own cells as vaccine factories. Unproven until last year, the technology has now catapulted to the forefront of the global fight against Covid.\nCureVac’s shot, though, is subtly different than its competitors, because it uses an unmodified form of mRNA.\nCureVac has said it plans to supply 300 million vaccine doses this year, enough to immunize 150 million people. Together with partners, it has said it will supply more than 1 billion doses in 2022.","news_type":1,"symbols_score_info":{"CVAC":0.9}},"isVote":1,"tweetType":1,"viewCount":2412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160476634,"gmtCreate":1623805539828,"gmtModify":1631889812879,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/160476634","repostId":"2143680537","repostType":4,"isVote":1,"tweetType":1,"viewCount":3951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187143489,"gmtCreate":1623747766241,"gmtModify":1631889812883,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"Nice !","listText":"Nice !","text":"Nice !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187143489","repostId":"1175897310","repostType":4,"repost":{"id":"1175897310","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://www.laohunote.com/m/news/1175897310?lang=zh_CN&edition=full","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga Earnings","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p><p><blockquote>本周的 IPO 阵容中可能会有两位数的公司上市。以下是本周上市的一些最大、最引人注目的公司。</blockquote></p><p> <b>AMTD Digital:</b>Asian digital solutions platform <b>AMTD Digital</b>(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p><p><blockquote><b>尚乘数码：</b>亚洲数字解决方案平台<b>尚乘数码</b>（纽约证券交易所代码：HKD）为合作伙伴提供风险解决方案和数字保险技术。该公司2020财年的收入为2160万美元，本财年前9个月的收入为1880万美元。该公司计划以6.80美元至8.20美元的价格出售1600万股美国存托凭证。</blockquote></p><p> <b>Molecular Partners:</b>Clinical stage biotechnology company <b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with <b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and <b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p><p><blockquote><b>分子伙伴：</b>临床阶段生物技术公司<b>分子伙伴</b>（纳斯达克股票代码：MOLN）isfocusedon 在传染病、肿瘤学和眼科等类别中使用其开创性的 DARPin 产品。该公司与<b>诺华</b>（纽约证券交易所代码：NVS）2020年，<b>安进公司</b>（纳斯达克股票代码：AMGN）2018 年和<b>艾伯维公司</b>（纽约证券交易所代码：ABBV）2011 年。诺华拥有该公司6%的股份。Molecular Partners 计划出售 300 万个广告。</blockquote></p><p> <b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p><p><blockquote><b>WalkMe：</b>以改变人类与技术互动的方式为使命，<b>随身行走</b>（纳斯达克股票代码：WKME）为组织提供解决方案。该公司拥有许多知名公司作为客户，包括雀巢和威立雅，这两家欧洲大公司在文件中被列为案例研究。</blockquote></p><p> WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p><p><blockquote>WalkMe 2020年的收入为1.48亿美元，2021年第一季度的收入为4270万美元。在过去的 12 个月里，该公司的收入同比增长了 34%。该公司有368家年收入在10万美元或以上的客户，22家年收入在100万美元或以上的客户。WalkMe 计划以 29 至 32 美元的价格出售 925 万股股票。</blockquote></p><p> <b>Convey Holding:</b>Health care company <b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p><p><blockquote><b>传送保持：</b>医疗保健公司<b>输送保持</b>（纽约证券交易所股票代码：CNVY）与美国 10 家最大的医疗保险优势公司中的 8 家合作。2020年，该公司拥有250万Medicare Advantage和160万处方药计划会员。该公司2020年收入为2.829亿美元。该公司 2021 年第一季度收入为 8260 万美元。Convey Holding 计划以 14 至 16 美元的价格出售 1,330 万股股票。</blockquote></p><p> <b>Angel Oak Mortgage:</b>Real estate finance company <b>Angel Oak Mortgage</b>(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p><p><blockquote><b>天使橡树抵押贷款：</b>房地产金融公司<b>天使橡树抵押贷款</b>（纽约证券交易所代码：AOMR）在美国收购并投资第一留置权非质量管理贷款和其他抵押资产。截至2021年第一季度末，该公司的资产为5.349亿美元。该公司选择作为房地产投资信托基金征税。Angel Oak Mortgage 寻求以 20 至 21 美元的价格出售 810 万股股票。</blockquote></p><p> <b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p><p><blockquote><b>莱尔免疫制药公司：</b>寻求颠覆T细胞重编程市场，<b>莱尔免疫制药公司</b>（纳斯达克股票代码：LYEL）打算在 2022 年底前提交四份 IND。该公司与<b>葛兰素史克</b>（纽约证券交易所股票代码：葛兰素史克）将于 2019 年达成一项交易，在预付 4500 万美元后，该交易将带来高达 4 亿美元的额外里程碑。</blockquote></p><p> GlaxoSmithKline owns 14% of Lyell and <b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p><p><blockquote>葛兰素史克拥有莱尔和<b>百时美施贵宝</b>（纽约证券交易所代码：BMY）拥有新基拥有该公司 5% 的股份。莱尔计划以16至18美元的价格出售2500万股股票。</blockquote></p><p> <b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p><p><blockquote><b>神韵疗法：</b>基因医药公司<b>神韵疗法</b>（纳斯达克：VERV）专注于心血管疾病。该公司计划以16至18美元的价格出售1180万股股票。</blockquote></p><p> <b>Atai Life Sciences:</b>Backedby <b>Palantir Technologies</b>(NYSE:PLTR) and <b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p><p><blockquote><b>阿泰生命科学：</b>支持<b>帕兰蒂尔技术公司</b>（纽约证券交易所代码：PLTR）和<b>Paypal控股</b>（纳斯达克股票代码：PYPL）创始人彼得·泰尔，<b>阿泰生命科学</b>（纳斯达克股票代码：ATAI）可能是本周备受瞩目的 IPO 之一。</blockquote></p><p> The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p><p><blockquote>该公司正在开发精神健康障碍的治疗方案。该公司有10个项目正在筹备中，有6项使能技术。该公司计划以 13 至 15 美元的价格出售 1,430 万股股票。</blockquote></p><p> <b>AiHui Shou International:</b>Pre-owned consumer electronics reseller <b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p><p><blockquote><b>爱惠寿国际：</b>二手消费电子产品经销商<b>爱回收国际</b>（纽约证券交易所代码：RERE）寻求让所有闲置商品重获新生。</blockquote></p><p> The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p><p><blockquote>公司的三条业务线--AHS Recycle、PJUT Marketplace 和 PaiPai Marketplace--帮助公司以 6.6% 的市场份额成为中国市场领导者。该公司2020年收入为7.415亿美元，2021年第一季度收入为2.311亿美元，同比增长119%。<b>京东</b>（纳斯达克股票代码：JD）将在IPO后拥有该公司32.3%的股份。该公司计划以 13 至 15 美元的价格出售 1620 万股美国存托凭证。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-06-15 10:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p><p><blockquote>本周的 IPO 阵容中可能会有两位数的公司上市。以下是本周上市的一些最大、最引人注目的公司。</blockquote></p><p> <b>AMTD Digital:</b>Asian digital solutions platform <b>AMTD Digital</b>(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p><p><blockquote><b>尚乘数码：</b>亚洲数字解决方案平台<b>尚乘数码</b>（纽约证券交易所代码：HKD）为合作伙伴提供风险解决方案和数字保险技术。该公司2020财年的收入为2160万美元，本财年前9个月的收入为1880万美元。该公司计划以6.80美元至8.20美元的价格出售1600万股美国存托凭证。</blockquote></p><p> <b>Molecular Partners:</b>Clinical stage biotechnology company <b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with <b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and <b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p><p><blockquote><b>分子伙伴：</b>临床阶段生物技术公司<b>分子伙伴</b>（纳斯达克股票代码：MOLN）isfocusedon 在传染病、肿瘤学和眼科等类别中使用其开创性的 DARPin 产品。该公司与<b>诺华</b>（纽约证券交易所代码：NVS）2020年，<b>安进公司</b>（纳斯达克股票代码：AMGN）2018 年和<b>艾伯维公司</b>（纽约证券交易所代码：ABBV）2011 年。诺华拥有该公司6%的股份。Molecular Partners 计划出售 300 万个广告。</blockquote></p><p> <b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p><p><blockquote><b>WalkMe：</b>以改变人类与技术互动的方式为使命，<b>随身行走</b>（纳斯达克股票代码：WKME）为组织提供解决方案。该公司拥有许多知名公司作为客户，包括雀巢和威立雅，这两家欧洲大公司在文件中被列为案例研究。</blockquote></p><p> WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p><p><blockquote>WalkMe 2020年的收入为1.48亿美元，2021年第一季度的收入为4270万美元。在过去的 12 个月里，该公司的收入同比增长了 34%。该公司有368家年收入在10万美元或以上的客户，22家年收入在100万美元或以上的客户。WalkMe 计划以 29 至 32 美元的价格出售 925 万股股票。</blockquote></p><p> <b>Convey Holding:</b>Health care company <b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p><p><blockquote><b>传送保持：</b>医疗保健公司<b>输送保持</b>（纽约证券交易所股票代码：CNVY）与美国 10 家最大的医疗保险优势公司中的 8 家合作。2020年，该公司拥有250万Medicare Advantage和160万处方药计划会员。该公司2020年收入为2.829亿美元。该公司 2021 年第一季度收入为 8260 万美元。Convey Holding 计划以 14 至 16 美元的价格出售 1,330 万股股票。</blockquote></p><p> <b>Angel Oak Mortgage:</b>Real estate finance company <b>Angel Oak Mortgage</b>(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p><p><blockquote><b>天使橡树抵押贷款：</b>房地产金融公司<b>天使橡树抵押贷款</b>（纽约证券交易所代码：AOMR）在美国收购并投资第一留置权非质量管理贷款和其他抵押资产。截至2021年第一季度末，该公司的资产为5.349亿美元。该公司选择作为房地产投资信托基金征税。Angel Oak Mortgage 寻求以 20 至 21 美元的价格出售 810 万股股票。</blockquote></p><p> <b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p><p><blockquote><b>莱尔免疫制药公司：</b>寻求颠覆T细胞重编程市场，<b>莱尔免疫制药公司</b>（纳斯达克股票代码：LYEL）打算在 2022 年底前提交四份 IND。该公司与<b>葛兰素史克</b>（纽约证券交易所股票代码：葛兰素史克）将于 2019 年达成一项交易，在预付 4500 万美元后，该交易将带来高达 4 亿美元的额外里程碑。</blockquote></p><p> GlaxoSmithKline owns 14% of Lyell and <b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p><p><blockquote>葛兰素史克拥有莱尔和<b>百时美施贵宝</b>（纽约证券交易所代码：BMY）拥有新基拥有该公司 5% 的股份。莱尔计划以16至18美元的价格出售2500万股股票。</blockquote></p><p> <b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p><p><blockquote><b>神韵疗法：</b>基因医药公司<b>神韵疗法</b>（纳斯达克：VERV）专注于心血管疾病。该公司计划以16至18美元的价格出售1180万股股票。</blockquote></p><p> <b>Atai Life Sciences:</b>Backedby <b>Palantir Technologies</b>(NYSE:PLTR) and <b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p><p><blockquote><b>阿泰生命科学：</b>支持<b>帕兰蒂尔技术公司</b>（纽约证券交易所代码：PLTR）和<b>Paypal控股</b>（纳斯达克股票代码：PYPL）创始人彼得·泰尔，<b>阿泰生命科学</b>（纳斯达克股票代码：ATAI）可能是本周备受瞩目的 IPO 之一。</blockquote></p><p> The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p><p><blockquote>该公司正在开发精神健康障碍的治疗方案。该公司有10个项目正在筹备中，有6项使能技术。该公司计划以 13 至 15 美元的价格出售 1,430 万股股票。</blockquote></p><p> <b>AiHui Shou International:</b>Pre-owned consumer electronics reseller <b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p><p><blockquote><b>爱惠寿国际：</b>二手消费电子产品经销商<b>爱回收国际</b>（纽约证券交易所代码：RERE）寻求让所有闲置商品重获新生。</blockquote></p><p> The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p><p><blockquote>公司的三条业务线--AHS Recycle、PJUT Marketplace 和 PaiPai Marketplace--帮助公司以 6.6% 的市场份额成为中国市场领导者。该公司2020年收入为7.415亿美元，2021年第一季度收入为2.311亿美元，同比增长119%。<b>京东</b>（纳斯达克股票代码：JD）将在IPO后拥有该公司32.3%的股份。该公司计划以 13 至 15 美元的价格出售 1620 万股美国存托凭证。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RERE":"爱回收","MOLN":"Molecular Partners AG","HKD":"尚乘数科","WKME":"WalkMe Ltd.","LYEL":"Lyell Immunopharma, Inc.","AOMR":"ANGEL OAK MORTGAGE REIT INC","NVS":"诺华","ATAI":"Atai Beckley Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1,"symbols_score_info":{"AOMR":0.9,"NVS":0.9,"LYEL":0.9,"ATAI":0.9,"WKME":0.9,"RERE":0.9,"CNVY":0.9,"MOLN":0.9,"HKD":0.9}},"isVote":1,"tweetType":1,"viewCount":2498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187149447,"gmtCreate":1623747753689,"gmtModify":1631889812888,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"Nice !","listText":"Nice !","text":"Nice !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187149447","repostId":"1175897310","repostType":4,"repost":{"id":"1175897310","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://www.laohunote.com/m/news/1175897310?lang=zh_CN&edition=full","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga Earnings","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p><p><blockquote>本周的 IPO 阵容中可能会有两位数的公司上市。以下是本周上市的一些最大、最引人注目的公司。</blockquote></p><p> <b>AMTD Digital:</b>Asian digital solutions platform <b>AMTD Digital</b>(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p><p><blockquote><b>尚乘数码：</b>亚洲数字解决方案平台<b>尚乘数码</b>（纽约证券交易所代码：HKD）为合作伙伴提供风险解决方案和数字保险技术。该公司2020财年的收入为2160万美元，本财年前9个月的收入为1880万美元。该公司计划以6.80美元至8.20美元的价格出售1600万股美国存托凭证。</blockquote></p><p> <b>Molecular Partners:</b>Clinical stage biotechnology company <b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with <b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and <b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p><p><blockquote><b>分子伙伴：</b>临床阶段生物技术公司<b>分子伙伴</b>（纳斯达克股票代码：MOLN）isfocusedon 在传染病、肿瘤学和眼科等类别中使用其开创性的 DARPin 产品。该公司与<b>诺华</b>（纽约证券交易所代码：NVS）2020年，<b>安进公司</b>（纳斯达克股票代码：AMGN）2018 年和<b>艾伯维公司</b>（纽约证券交易所代码：ABBV）2011 年。诺华拥有该公司6%的股份。Molecular Partners 计划出售 300 万个广告。</blockquote></p><p> <b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p><p><blockquote><b>WalkMe：</b>以改变人类与技术互动的方式为使命，<b>随身行走</b>（纳斯达克股票代码：WKME）为组织提供解决方案。该公司拥有许多知名公司作为客户，包括雀巢和威立雅，这两家欧洲大公司在文件中被列为案例研究。</blockquote></p><p> WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p><p><blockquote>WalkMe 2020年的收入为1.48亿美元，2021年第一季度的收入为4270万美元。在过去的 12 个月里，该公司的收入同比增长了 34%。该公司有368家年收入在10万美元或以上的客户，22家年收入在100万美元或以上的客户。WalkMe 计划以 29 至 32 美元的价格出售 925 万股股票。</blockquote></p><p> <b>Convey Holding:</b>Health care company <b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p><p><blockquote><b>传送保持：</b>医疗保健公司<b>输送保持</b>（纽约证券交易所股票代码：CNVY）与美国 10 家最大的医疗保险优势公司中的 8 家合作。2020年，该公司拥有250万Medicare Advantage和160万处方药计划会员。该公司2020年收入为2.829亿美元。该公司 2021 年第一季度收入为 8260 万美元。Convey Holding 计划以 14 至 16 美元的价格出售 1,330 万股股票。</blockquote></p><p> <b>Angel Oak Mortgage:</b>Real estate finance company <b>Angel Oak Mortgage</b>(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p><p><blockquote><b>天使橡树抵押贷款：</b>房地产金融公司<b>天使橡树抵押贷款</b>（纽约证券交易所代码：AOMR）在美国收购并投资第一留置权非质量管理贷款和其他抵押资产。截至2021年第一季度末，该公司的资产为5.349亿美元。该公司选择作为房地产投资信托基金征税。Angel Oak Mortgage 寻求以 20 至 21 美元的价格出售 810 万股股票。</blockquote></p><p> <b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p><p><blockquote><b>莱尔免疫制药公司：</b>寻求颠覆T细胞重编程市场，<b>莱尔免疫制药公司</b>（纳斯达克股票代码：LYEL）打算在 2022 年底前提交四份 IND。该公司与<b>葛兰素史克</b>（纽约证券交易所股票代码：葛兰素史克）将于 2019 年达成一项交易，在预付 4500 万美元后，该交易将带来高达 4 亿美元的额外里程碑。</blockquote></p><p> GlaxoSmithKline owns 14% of Lyell and <b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p><p><blockquote>葛兰素史克拥有莱尔和<b>百时美施贵宝</b>（纽约证券交易所代码：BMY）拥有新基拥有该公司 5% 的股份。莱尔计划以16至18美元的价格出售2500万股股票。</blockquote></p><p> <b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p><p><blockquote><b>神韵疗法：</b>基因医药公司<b>神韵疗法</b>（纳斯达克：VERV）专注于心血管疾病。该公司计划以16至18美元的价格出售1180万股股票。</blockquote></p><p> <b>Atai Life Sciences:</b>Backedby <b>Palantir Technologies</b>(NYSE:PLTR) and <b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p><p><blockquote><b>阿泰生命科学：</b>支持<b>帕兰蒂尔技术公司</b>（纽约证券交易所代码：PLTR）和<b>Paypal控股</b>（纳斯达克股票代码：PYPL）创始人彼得·泰尔，<b>阿泰生命科学</b>（纳斯达克股票代码：ATAI）可能是本周备受瞩目的 IPO 之一。</blockquote></p><p> The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p><p><blockquote>该公司正在开发精神健康障碍的治疗方案。该公司有10个项目正在筹备中，有6项使能技术。该公司计划以 13 至 15 美元的价格出售 1,430 万股股票。</blockquote></p><p> <b>AiHui Shou International:</b>Pre-owned consumer electronics reseller <b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p><p><blockquote><b>爱惠寿国际：</b>二手消费电子产品经销商<b>爱回收国际</b>（纽约证券交易所代码：RERE）寻求让所有闲置商品重获新生。</blockquote></p><p> The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p><p><blockquote>公司的三条业务线--AHS Recycle、PJUT Marketplace 和 PaiPai Marketplace--帮助公司以 6.6% 的市场份额成为中国市场领导者。该公司2020年收入为7.415亿美元，2021年第一季度收入为2.311亿美元，同比增长119%。<b>京东</b>（纳斯达克股票代码：JD）将在IPO后拥有该公司32.3%的股份。该公司计划以 13 至 15 美元的价格出售 1620 万股美国存托凭证。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings<blockquote>IPO 预览：WalkMe、Atai Life Sciences 亮点本周众多产品</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-06-15 10:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p><p><blockquote>本周的 IPO 阵容中可能会有两位数的公司上市。以下是本周上市的一些最大、最引人注目的公司。</blockquote></p><p> <b>AMTD Digital:</b>Asian digital solutions platform <b>AMTD Digital</b>(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p><p><blockquote><b>尚乘数码：</b>亚洲数字解决方案平台<b>尚乘数码</b>（纽约证券交易所代码：HKD）为合作伙伴提供风险解决方案和数字保险技术。该公司2020财年的收入为2160万美元，本财年前9个月的收入为1880万美元。该公司计划以6.80美元至8.20美元的价格出售1600万股美国存托凭证。</blockquote></p><p> <b>Molecular Partners:</b>Clinical stage biotechnology company <b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with <b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and <b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p><p><blockquote><b>分子伙伴：</b>临床阶段生物技术公司<b>分子伙伴</b>（纳斯达克股票代码：MOLN）isfocusedon 在传染病、肿瘤学和眼科等类别中使用其开创性的 DARPin 产品。该公司与<b>诺华</b>（纽约证券交易所代码：NVS）2020年，<b>安进公司</b>（纳斯达克股票代码：AMGN）2018 年和<b>艾伯维公司</b>（纽约证券交易所代码：ABBV）2011 年。诺华拥有该公司6%的股份。Molecular Partners 计划出售 300 万个广告。</blockquote></p><p> <b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p><p><blockquote><b>WalkMe：</b>以改变人类与技术互动的方式为使命，<b>随身行走</b>（纳斯达克股票代码：WKME）为组织提供解决方案。该公司拥有许多知名公司作为客户，包括雀巢和威立雅，这两家欧洲大公司在文件中被列为案例研究。</blockquote></p><p> WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p><p><blockquote>WalkMe 2020年的收入为1.48亿美元，2021年第一季度的收入为4270万美元。在过去的 12 个月里，该公司的收入同比增长了 34%。该公司有368家年收入在10万美元或以上的客户，22家年收入在100万美元或以上的客户。WalkMe 计划以 29 至 32 美元的价格出售 925 万股股票。</blockquote></p><p> <b>Convey Holding:</b>Health care company <b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p><p><blockquote><b>传送保持：</b>医疗保健公司<b>输送保持</b>（纽约证券交易所股票代码：CNVY）与美国 10 家最大的医疗保险优势公司中的 8 家合作。2020年，该公司拥有250万Medicare Advantage和160万处方药计划会员。该公司2020年收入为2.829亿美元。该公司 2021 年第一季度收入为 8260 万美元。Convey Holding 计划以 14 至 16 美元的价格出售 1,330 万股股票。</blockquote></p><p> <b>Angel Oak Mortgage:</b>Real estate finance company <b>Angel Oak Mortgage</b>(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p><p><blockquote><b>天使橡树抵押贷款：</b>房地产金融公司<b>天使橡树抵押贷款</b>（纽约证券交易所代码：AOMR）在美国收购并投资第一留置权非质量管理贷款和其他抵押资产。截至2021年第一季度末，该公司的资产为5.349亿美元。该公司选择作为房地产投资信托基金征税。Angel Oak Mortgage 寻求以 20 至 21 美元的价格出售 810 万股股票。</blockquote></p><p> <b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p><p><blockquote><b>莱尔免疫制药公司：</b>寻求颠覆T细胞重编程市场，<b>莱尔免疫制药公司</b>（纳斯达克股票代码：LYEL）打算在 2022 年底前提交四份 IND。该公司与<b>葛兰素史克</b>（纽约证券交易所股票代码：葛兰素史克）将于 2019 年达成一项交易，在预付 4500 万美元后，该交易将带来高达 4 亿美元的额外里程碑。</blockquote></p><p> GlaxoSmithKline owns 14% of Lyell and <b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p><p><blockquote>葛兰素史克拥有莱尔和<b>百时美施贵宝</b>（纽约证券交易所代码：BMY）拥有新基拥有该公司 5% 的股份。莱尔计划以16至18美元的价格出售2500万股股票。</blockquote></p><p> <b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p><p><blockquote><b>神韵疗法：</b>基因医药公司<b>神韵疗法</b>（纳斯达克：VERV）专注于心血管疾病。该公司计划以16至18美元的价格出售1180万股股票。</blockquote></p><p> <b>Atai Life Sciences:</b>Backedby <b>Palantir Technologies</b>(NYSE:PLTR) and <b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p><p><blockquote><b>阿泰生命科学：</b>支持<b>帕兰蒂尔技术公司</b>（纽约证券交易所代码：PLTR）和<b>Paypal控股</b>（纳斯达克股票代码：PYPL）创始人彼得·泰尔，<b>阿泰生命科学</b>（纳斯达克股票代码：ATAI）可能是本周备受瞩目的 IPO 之一。</blockquote></p><p> The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p><p><blockquote>该公司正在开发精神健康障碍的治疗方案。该公司有10个项目正在筹备中，有6项使能技术。该公司计划以 13 至 15 美元的价格出售 1,430 万股股票。</blockquote></p><p> <b>AiHui Shou International:</b>Pre-owned consumer electronics reseller <b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p><p><blockquote><b>爱惠寿国际：</b>二手消费电子产品经销商<b>爱回收国际</b>（纽约证券交易所代码：RERE）寻求让所有闲置商品重获新生。</blockquote></p><p> The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p><p><blockquote>公司的三条业务线--AHS Recycle、PJUT Marketplace 和 PaiPai Marketplace--帮助公司以 6.6% 的市场份额成为中国市场领导者。该公司2020年收入为7.415亿美元，2021年第一季度收入为2.311亿美元，同比增长119%。<b>京东</b>（纳斯达克股票代码：JD）将在IPO后拥有该公司32.3%的股份。该公司计划以 13 至 15 美元的价格出售 1620 万股美国存托凭证。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RERE":"爱回收","MOLN":"Molecular Partners AG","HKD":"尚乘数科","WKME":"WalkMe Ltd.","LYEL":"Lyell Immunopharma, Inc.","AOMR":"ANGEL OAK MORTGAGE REIT INC","NVS":"诺华","ATAI":"Atai Beckley Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1,"symbols_score_info":{"AOMR":0.9,"NVS":0.9,"LYEL":0.9,"ATAI":0.9,"WKME":0.9,"RERE":0.9,"CNVY":0.9,"MOLN":0.9,"HKD":0.9}},"isVote":1,"tweetType":1,"viewCount":2489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185070853,"gmtCreate":1623628764172,"gmtModify":1631889812897,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/185070853","repostId":"1146430910","repostType":4,"isVote":1,"tweetType":1,"viewCount":2309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188481300,"gmtCreate":1623458741300,"gmtModify":1631889812898,"author":{"id":"3581590310925129","authorId":"3581590310925129","name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581590310925129","idStr":"3581590310925129"},"themes":[],"title":"","htmlText":"Pls comment thanks","listText":"Pls comment thanks","text":"Pls comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/188481300","repostId":"2142204074","repostType":4,"isVote":1,"tweetType":1,"viewCount":2516,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}